Nichols & Pratt Advisers LLP MA Sells 633 Shares of Stryker Co. (NYSE:SYK)

Nichols & Pratt Advisers LLP MA lowered its position in Stryker Co. (NYSE:SYK) by 1.2% during the 4th quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The institutional investor owned 52,325 shares of the medical technology company’s stock after selling 633 shares during the quarter. Stryker makes up about 1.1% of Nichols & Pratt Advisers LLP MA’s portfolio, making the stock its 27th biggest position. Nichols & Pratt Advisers LLP MA’s holdings in Stryker were worth $15,669,000 at the end of the most recent reporting period.

Other hedge funds and other institutional investors also recently bought and sold shares of the company. Bremer Bank National Association boosted its position in Stryker by 4.0% during the 4th quarter. Bremer Bank National Association now owns 888 shares of the medical technology company’s stock valued at $266,000 after acquiring an additional 34 shares in the last quarter. Simon Quick Advisors LLC raised its stake in Stryker by 3.0% in the 4th quarter. Simon Quick Advisors LLC now owns 1,158 shares of the medical technology company’s stock worth $347,000 after acquiring an additional 34 shares during the last quarter. Consolidated Portfolio Review Corp raised its stake in Stryker by 3.6% in the 4th quarter. Consolidated Portfolio Review Corp now owns 983 shares of the medical technology company’s stock worth $294,000 after acquiring an additional 34 shares during the last quarter. FourThought Financial Partners LLC raised its stake in shares of Stryker by 3.3% during the 4th quarter. FourThought Financial Partners LLC now owns 1,076 shares of the medical technology company’s stock valued at $322,000 after buying an additional 34 shares during the last quarter. Finally, Catalyst Financial Partners LLC boosted its position in Stryker by 3.0% in the 4th quarter. Catalyst Financial Partners LLC now owns 1,154 shares of the medical technology company’s stock worth $346,000 after purchasing an additional 34 shares in the last quarter. Institutional investors own 77.09% of the company’s stock.

Stryker Price Performance

Shares of Stryker stock traded down $0.53 on Friday, hitting $330.33. The company’s stock had a trading volume of 382,156 shares, compared to its average volume of 1,316,786. Stryker Co. has a 52-week low of $249.98 and a 52-week high of $361.41. The company has a quick ratio of 0.99, a current ratio of 1.71 and a debt-to-equity ratio of 0.56. The firm has a fifty day moving average price of $345.24 and a 200-day moving average price of $318.99. The company has a market capitalization of $125.84 billion, a P/E ratio of 37.78, a price-to-earnings-growth ratio of 2.54 and a beta of 0.91.

Stryker (NYSE:SYK) last released its quarterly earnings data on Tuesday, April 30th. The medical technology company reported $2.50 EPS for the quarter, topping the consensus estimate of $2.36 by $0.14. The business had revenue of $5.24 billion for the quarter, compared to analyst estimates of $5.10 billion. Stryker had a net margin of 16.03% and a return on equity of 23.05%. The business’s revenue for the quarter was up 9.7% compared to the same quarter last year. During the same period in the previous year, the firm earned $2.14 EPS. On average, equities research analysts expect that Stryker Co. will post 11.94 earnings per share for the current fiscal year.

Stryker Dividend Announcement

The business also recently disclosed a quarterly dividend, which will be paid on Wednesday, July 31st. Stockholders of record on Friday, June 28th will be issued a dividend of $0.80 per share. The ex-dividend date is Friday, June 28th. This represents a $3.20 annualized dividend and a dividend yield of 0.97%. Stryker’s payout ratio is currently 36.53%.

Wall Street Analysts Forecast Growth

A number of equities analysts recently weighed in on the company. Piper Sandler upped their price target on Stryker from $375.00 to $380.00 and gave the stock an “overweight” rating in a report on Wednesday, May 1st. Stifel Nicolaus boosted their price objective on shares of Stryker from $350.00 to $375.00 and gave the company a “buy” rating in a report on Wednesday, May 1st. Citigroup increased their target price on Stryker from $362.00 to $406.00 and gave the stock a “buy” rating in a research note on Wednesday, April 3rd. StockNews.com upgraded shares of Stryker from a “hold” rating to a “buy” rating in a report on Tuesday, January 23rd. Finally, Royal Bank of Canada lifted their price target on shares of Stryker from $360.00 to $386.00 and gave the stock an “outperform” rating in a research note on Monday, April 15th. Four equities research analysts have rated the stock with a hold rating and fifteen have issued a buy rating to the company’s stock. According to data from MarketBeat, the stock has a consensus rating of “Moderate Buy” and a consensus price target of $365.94.

Insider Transactions at Stryker

In other Stryker news, CAO William E. Berry, Jr. sold 7,690 shares of the stock in a transaction that occurred on Thursday, March 7th. The shares were sold at an average price of $358.48, for a total value of $2,756,711.20. Following the completion of the sale, the chief accounting officer now owns 3,675 shares of the company’s stock, valued at $1,317,414. The sale was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. Insiders own 5.50% of the company’s stock.

Stryker Company Profile

Stryker Corporation operates as a medical technology company. The company operates through two segments, MedSurg and Neurotechnology, and Orthopaedics and Spine. The Orthopaedics and Spine segment provides implants for use in total joint replacements, such as hip, knee and shoulder, and trauma and extremities surgeries.